CD45RB Is a Novel Molecular Therapeutic Target to Inhibit Aβ Peptide-Induced Microglial MAPK Activation

Yuyan Zhu, Huayan Hou, William V. Nikolic et al. · 2008

Read CD45RB Is a Novel Molecular Therapeutic Target to Inhibit Aβ Peptide-Induced Microglial MAPK Activation by Yuyan Zhu, Huayan Hou, William V. Nikolic et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0002135.txt.

Description

Yuyan Zhu, Huayan Hou, William Nikolic, and co-authors studied brain immune cells in Alzheimer's disease, in a 2008 PLOS ONE paper. Microglia are the brain's own defense cells, and in this disease they switch on in ways that may harm nerve cells. Signals through pathways called MAPK drive much of that response when the cells meet amyloid-beta, the protein that builds up in patients' brains.

Earlier work by the group showed that a surface protein called CD45 calms this response. Here they point to a related form, CD45RB, as a drug target. Adjusting it might lower the harmful side of microglial activity while leaving the brain's defenses in place.

Catalog record

CREATORYuyan Zhu, Huayan Hou, William V. Nikolic et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002135

Browse the full library · About the Tower of Babel